Idiopathic intracranial hypertension: a step change in Understanding the disease mechanisms
GLP-1 receptor agonists act primarily by enhancing postprandial insulin secretion and suppressing glucagon release, leading to improved glycemic control (48, 49)
Although these medications were originally produced to treat patients with type 2 diabetes, their role within the field of medicine has expanded into the treatment of obesity
Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injectionsite reactions, allergic symptoms) or if there is no clear returntobaseline window between doses
Heart health should not be ignored either, as underlying heart disease might be influenced by the treatment
At present, the researchers do not recommend altering patient preparation or stopping GLP-1 agonists prior to FDG PET/CT scans